Literature DB >> 17208597

Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease.

Jennifer Y Lee1, Ronald A Simon, Donald D Stevenson.   

Abstract

BACKGROUND: Aspirin desensitization followed by daily aspirin therapy is effective add-on treatment for patients with aspirin-exacerbated respiratory disease. Prior studies used 650 mg of aspirin twice daily, but studies at lower dosages were inconclusive.
OBJECTIVE: We sought to determine the optimal daily dosage of aspirin treatment.
METHODS: We studied 137 patients who had undergone successful aspirin desensitization and randomized them into 2 groups, 650 mg twice daily versus 325 mg twice daily. After 1 month, patients either increased or decreased their dosage based on their symptom control and continued that dosage for the remainder of the year.
RESULTS: Patients taking either 650 mg twice daily or 325 mg twice daily showed significant improvements in number of sinus infections, sinus operations, and hospitalizations for asthma (all P < .0001). Anosmia, nasal/sinus symptoms, and asthma symptoms also improved in both groups (all P < .03). Systemic corticosteroid dosages decreased by 3- and 4-fold in the 325 mg twice daily and 650 mg twice daily groups, respectively. Of the 137 patients, 32 had adverse effects from or discontinued aspirin therapy: 14 (44%) of 32 from the group randomized to taking 650 mg twice daily and 18 (56%) of 32 from the group randomized to 325 mg twice daily. The most common adverse effect was dyspepsia.
CONCLUSION: Both dosages were efficacious, and side effects occurred in both groups at similar frequencies. Some patients initially taking 325 mg twice daily required an increase to 650 mg twice daily for optimal symptom control. CLINICAL IMPLICATIONS: We recommend that patients begin daily aspirin therapy with 650 mg twice daily and subsequently decrease to the lowest effective dosage (usually 325 mg twice daily).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17208597     DOI: 10.1016/j.jaci.2006.09.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  36 in total

1.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

Review 2.  [Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease].

Authors:  C Umbreit; J C Virchow; C Thorn; K Hörmann; L Klimek; O Pfaar
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

Review 3.  Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations.

Authors:  Newton Li; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2015 Sep-Oct       Impact factor: 2.587

4.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

Review 5.  Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD).

Authors:  Ronald A Simon; Kristen M Dazy; Jeremy D Waldram
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

6.  Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.

Authors:  Kathleen Lee-Sarwar; Christina Johns; Tanya M Laidlaw; Katherine N Cahill
Journal:  J Allergy Clin Immunol Pract       Date:  2015-01-26

Review 7.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 8.  Asthma: clinical expression and molecular mechanisms.

Authors:  Robert F Lemanske; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

9.  Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.

Authors:  Sharan J Shah; Waleed M Abuzeid; Anusha Ponduri; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; David Rosenstreich; Denisa Ferastraoaru; Elina Jerschow
Journal:  Int Forum Allergy Rhinol       Date:  2019-09-30       Impact factor: 3.858

Review 10.  Update on recent advances in the management of aspirin exacerbated respiratory disease.

Authors:  Nami Shrestha Palikhe; Joo-Hee Kim; Hae-Sim Park
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.